Cergutuzumab amunaleukin

DB14874Investigational

Cergutuzumab amunaleukin is under investigation in clinical trial NCT02004106 (A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors).

Mechanism: Pharmacologically active on Carcinoembryonic antigen, Cell adhesion molecule CEACAM5, and Interleukin-2 receptor
Curator reviewed
Code names: RO6895882

Resolves to

Compound

UNII48FCG62C25CAS1509916-03-3

Targets

Q14081Carcinoembryonic antigenP06731CEACAM5

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cergutuzumab amunaleukin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account